Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital

Century Therapeutics (NASDAQ:IPSC) had its target price reduced by research analysts at Chardan Capital from $11.00 to $7.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other research firms also recently weighed in on IPSC. Piper Sandler dropped their target price on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Thursday. Guggenheim dropped their price objective on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $5.00.

Century Therapeutics Stock Up 0.9 %

Shares of Century Therapeutics stock opened at $0.56 on Monday. The firm has a market cap of $47.19 million, a PE ratio of -0.30 and a beta of 1.75. Century Therapeutics has a 52 week low of $0.52 and a 52 week high of $4.50. The business’s fifty day simple moving average is $0.74 and its 200-day simple moving average is $1.15.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. The company had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.67 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. As a group, equities analysts expect that Century Therapeutics will post -1.61 earnings per share for the current year.

Institutional Trading of Century Therapeutics

Several hedge funds have recently modified their holdings of IPSC. Marshall Wace LLP purchased a new stake in Century Therapeutics during the 4th quarter worth about $36,000. Jane Street Group LLC grew its position in shares of Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after buying an additional 29,992 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Century Therapeutics during the fourth quarter worth approximately $52,000. Sei Investments Co. acquired a new stake in Century Therapeutics in the fourth quarter valued at approximately $53,000. Finally, Two Sigma Investments LP purchased a new position in Century Therapeutics in the fourth quarter worth approximately $67,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.